Karolinska universitetssjukhuset - Solna

Solna 17176

5 studies enrolling now · 14 studies all time

What they study most

Acute Lymphoblastic Leukemia (ALL), Advanced or Metastatic Gastric or Gastroesophageal Cancer, Advanced or Metastatic Solid Tumor, Arthritis, Psoriatic, Breast Cancer, Chronic Cutaneous Lupus Erythematosus, Colitis, Ulcerative, Esophageal Squamous Cell Carcinoma, Graft Vs Host Disease, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Hepatitis C, Chronic

Studies at this site

• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS — Recruiting now
• A Study of Pitolisant in Patients With Prader-Willi Syndrome — Recruiting now
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus — Enrolling by invitation
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis — Completed
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Completed
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Running, not enrolling
• Futibatinib in Patients With Specific FGFR Aberrations — Stopped early
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed